Nanosonics Limited · ASX:NAN
Nanosonics — FY2025 Earnings Presentation
34 slides from Nanosonics's earnings presentation, 2025
Slide 1: Infection Prevention. For Life.
DRAFT – v4 Infection Prevention. For Life. INVESTOR PRESENTATION 2025 Michael Kavanagh Jason Burriss FULL YEAR RESULTS CEO and President CFO
Slide 2: FY25 financial highlights
FY25 financial highlights Strong revenue and profit growth demonstrating strength of recurring revenue business model TOTAL REVENUE RECURRING REVENUE CAPITAL REVENUE (CONSUMABLES & SERVICE) $198.6M $146.1M $52.5M 17% YoY 20% YoY 9% YoY 14% CC1 CONSOLIDATED GROSS PROFIT MARGIN OPERATING EXPENSES PROF
Slide 3: Delivering key milestones in FY25
Delivering key milestones in FY25 Strong foundations to achieve the next growth horizon Innovation CORIS® FDA De Novo trophon3® and trophon2® 7 new patent families clearance Plus development Operations Consumables Service infrastructure CORIS supply chain manufacturing facility expanded to support &
Slide 4: 37,000 devices driving scalable recurring revenue growth
37,000 devices driving scalable recurring revenue growth Approximately 28 million patients protected annually from the risk of cross contamination GLOBAL CUMULATIVE INSTALLED BASE (DEVICES)1 6% vs PCP RECURRING REVENUE ($M) 20% vs PCP With a critical mass of 37,000 units, the large and growing insta
Slide 5: Customer value expansion
Customer value expansion 20% growth in recurring revenue, now representing 73% of total revenue RECURRING REVENUE ($M) Growth across all recurring revenue categories 20% vs PCP CONSUMABLES/SPARE PARTS AND SERVICE: 146.1 121.8 29.4 18% Core consumables and spare 111.8 growth on pcp parts: Sonex/NanoN
Slide 6: Installation of 3,870 trophon devices drives 9% growth in capital revenue
Installation of 3,870 trophon devices drives 9% growth in capital revenue CAPITAL REVENUE ($M) 9% vs PCP NEW INSTALLED BASE 2,210 units 54.2 52.5 48.2 37.7 UPGRADES 26.7 1,660 units FY21 FY22 FY23 FY24 FY25 Nanosonics Limited | Full Year Results 2025 | 6
Slide 7: FY25 full year financial results
FY25 full year financial results
Slide 8: Driving value creation
Driving value creation Trusted brand in automated high level disinfection with over 37,000 installed base Customer value expansion powering high margin recurring revenue. Disciplined capital allocation driving operating leverage and EBIT growth today. Strong cash generation and high return on capita
Slide 9: Profit & Loss summary
Profit & Loss summary Operating profit before tax up 72% $ millions FY25 FY24 Change % Capital revenue 52.5 48.2 9% Recurring revenue 146.1 121.8 20% • Total revenue growth of 17% to $198.6 million (14% in cc)1 Total revenue 198.6 170.0 17% • Operating expenses of $138.7 million, up 10% on pcp
Slide 10: Global revenue up 17% to $198.6 million
Global revenue up 17% to $198.6 million 17% GLOBAL REVENUE ($M) vs PCP 198.6 Recurring revenue from consumables & service, up 20% on pcp to $146.1 million 170.0 166.0 • 17% growth in volume driven by increased cumulative installed base and ultrasound procedural growth • 3% average pricing growth acr
Slide 11: Revenue growth across all regions
Revenue growth across all regions NORTH AMERICA ($M) EUROPE, UK AND MIDDLE EAST ($M) ASIA PACIFIC ($M) 17% vs PCP 180.4 154.2 150.4 22%vs PCP 12.2 131.0 20% vs PCP 10.1 101.4 109.2 4% 8.1 vs PCP 7.5 10.2 23% vs PCP 5.8 6.0 8.3 4.2 6.2 4.3 15% 4.9 vs PCP 48.9 45.0 49.4 10% vs PCP 3.3 1.9 1.8 2.0 15%
Slide 12: Regional trophon adoption
Regional trophon adoption NORTH AMERICA EUROPE, UK AND MIDDLE EAST ASIA PACIFIC CUMULATIVE INSTALLED BASE 6% 9% 4% vs PCP vs PCP vs PCP 32,310 30,390 28,390 1,920 New IB 2,430 200 New IB 90 New IB 2,230 2,170 2,260 (4% vs pcp) 2,010 (9% vs pcp) 2,050 (25% vs pcp) FY23 FY24 FY25 FY23 FY24 FY25 FY2
Slide 13: Gross profit margin 78.2%
Gross profit margin 78.2% FY25 gross profit margin rate improved 0.3% to 78.2% High gross profit margin supported by recurring revenue. GROSS MARGIN RATE Tariff impact during the period was $0.5m, part mitigated through inventory levels already held in the USA. FY26 gross margin 78.0% 79.7% 77.9% 78
Slide 14: Measured growth across operating expenses
Measured growth across operating expenses OPERATING EXPENSES ($M) Operational expenses in FY25: 10% vs FY24 • 43% invested in core revenue generating markets to drive ongoing growth $72.2m • 27% invested in infrastructure and capability for today and the future 138.7 125.6 114.2 • 25% invested in R&
Slide 15: Strong cash flow and cash balance
Strong cash flow and cash balance Cash & cash equivalents of $161.6m provides a strong foundation for strategic investments CASH FLOW ($M) CASH BALANCE ($M) 161.6 32.0 129.6 112.2 96.0 94.5 17.1 17.4 4.9 -2.2 FY21 FY22 FY23 FY24 FY25 FY21 FY22 FY23 FY24 FY25 FY25 cash flow growth in line with EBIT g
Slide 16: Strength and scalability of trophon only business
Strength and scalability of trophon only business Unaudited P&L1 $ millions FY25 FY24 Change % Capital revenue 52.5 48.2 9% Consumables and service revenue 146.1 121.8 20% • EBIT $48.4 million for trophon only business, up 33% vs pcp. Total revenue 198.6 170.0 17% Gross profit 155.4 132.4 17
Slide 17: Strategic growth drivers in ultrasound reprocessing
Strategic growth drivers in ultrasound reprocessing
Slide 18: Key trophon growth drivers
Key trophon growth drivers Capital Capital software upgrades Trophon2 Plus - trophon3 - ongoing new Accelerate upgrade adoption – software upgrade package installed base growth approximately 10,000 EPR opportunity, for internationally through deeper device opportunity for upgrade approximately 20,00
Slide 19: Market leadership through innovation
Market leadership through innovation Introducing trophon3 and the trophon2 Plus software package 1 2 3 Over 40% faster than Expanded connectivity New digital traceability previous generations and digital integration through customer’s of trophon. capabilities. DICOM imaging database. 4 5 6 Fully pro
Slide 20: Transforming endoscope reprocessing
Transforming endoscope reprocessing
Slide 21: CORIS milestones to commercialisation
CORIS milestones to commercialisation1 FY25 milestones USA Consumables Peer review Publication and Regional Clinical Simulation / FDA De Novo Device manufacturing manufacturing Podium Presentations on superior Customer education labs clearance & supply chain established site registered efficacy esta
Slide 22: Endoscopy: a large and growing market
Endoscopy: a large and growing market 60 million endoscopy procedures are conducted each year across major markets1 Annual Procedure Growth Volume (m) Rate 18.1 Upper GI 60m+ U.S.A. 33.7 +5.4% Projected procedure growth rate at 6% per annum. 1 GI 45.2 20.1 Colonoscopy 75% of procedures are upper and
Slide 23: Established endoscope reprocessing standards in place
Established endoscope reprocessing standards in place Strict reprocessing standards in place globally Current manual cleaning is universally recognised as the most important step and difficult step in reprocessing Global Standards/ World Gastroenterology Organisation (WGO) Guidelines ISO15883-4 GENC
Slide 24: Manual cleaning remains a challenge
Manual cleaning remains a challenge Lengthy process with 55 to 200 steps prone to error and variability Complex internal architecture of endoscopes makes manual cleaning extremely difficult with some channels inaccessible for brushing Often manual cleaning isn’t performed correctly1 Manual cleaning
Slide 25: Contamination persists and adverse events grow
Contamination persists and adverse events grow Harmful contamination & biofilm persists More than 35,000 adverse events in 2024, according to 5 despite reprocessing FDA MAUDE database • GI endoscopes and bronchoscopes have been associated with far more outbreaks of infections (>130 outbreaks) than a
Slide 26: CORIS addresses the challenges of manual cleaning
CORIS addresses the challenges of manual cleaning More efficacious CORIS uses a unique mechanism of action, that removes tough soils & biofilms that form in all the channels, including those that cannot be brushed today. More repeatable As an automated solution, it controls cleaning to each individu
Slide 27: Significant growth opportunity
Significant growth opportunity CORIS business model & revenue streams Number of daily cycles per machine expected to be a Capital equipment to be installed multiple of trophon cycles at a in endoscope reprocessing higher price to trophon cycle. centres. Note, current cost of manual Capital equipment
Slide 28: FY26 business outlook
FY26 business outlook Infection Prevention. Fer Lif
Slide 29: FY26 guidance at constant currency
FY26 guidance at constant currency1 Continuing growth and investment for future TOTAL REVENUE • Ongoing capital revenue growth with launch of trophon3 and trophon2 Plus driving new IB and upgrades. • Continuing recurring revenue growth from customer value expansion strategies. $215m to $223m • Minim
Slide 30: Sustainability
Sustainability FY25 renewable energy FY26 sustainability targets achievements • Use 100% renewable energy source for Australian and US business operations by end of FY25 to significantly reduce both scope 1 and 2 Caring for our Caring for our Caring for our Caring for our emissions. customers & pa
Slide 31: Summary & strategic growth drivers
Summary & strategic growth drivers Strong operational and financial performance in FY25, at top end of upgraded guidance Innovation delivering new products, trophon3 and trophon2 FY26 Beyond Plus, a software upgrade package, to support market leadership. Continued customer value expansion Multiple r
Slide 32: Appendix
trophond? trophoni3® trophon Appendix Infection Prevention For Lite nanosonics (eZ
Slide 33: Income tax & constant currency disclosure
Income tax & constant currency disclosure Income tax Constant currency Constant currency removes the impact of exchange rate movements to facilitate • Effective income tax for the period was 7.2%. comparability of operational performance. This is done by (1) converting the current year sales, costs
Slide 34: Disclaimer
Disclaimer This presentation is intended to provide a general outline only and is not intended to No representation, warranty or assurance (express or implied) is given or made in be a definitive statement on the subject matter covered in it. The information in this relation to any forward looking s